ROBERT FARLEY: Open Payments
NPI 1942660980 · BRYANT, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$516 in 29 payments from 9 companies in 2025. Trend: 2023 $137 · 2024 $295 · 2025 $516
Food & beverage: $516
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $223 |
| E.R. Squibb & Sons, L.L.C. | 4 | $70 |
| Abbott Laboratories | 2 | $52 |
| Alnylam Pharmaceuticals Inc. | 3 | $48 |
| Philips North America LLC | 2 | $33 |
| Boston Scientific Corporation | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| AtriCure, Inc. | 1 | $18 |
| BridgeBio Pharma, Inc. | 1 | $17 |
Products named: LEQVIO, CAMZYOS, AMVUTTRA, BodyGuardian, NAVITOR, CARDIOMEMS, EVKEEZA, ECC Solutions.
Industry payments across AR — which companies pay providers there.
